World journal of gastroenterology · 2003
Is the expression of gamma-glutamyl transpeptidase messenger RNA an indicator of biological behavior in recurrent hepatocellular carcinoma?
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sheen I-Shyan, Jeng Kuo-Shyang, Tsai Yi-Chun
Аннотация
AIM: To investigate the correlation between gamma-glutamyl transpeptidase (gamma-GTP) expression in the primary HCC and post-resection recurrence and its biological behaviors.
METHODS: Forty consecutive patients having curative resection for HCC were included in this study. The primers for reverse-transcription polymerase chain reaction (RT-PCR) were corresponding to the 5'-noncoding human gamma-GTP mRNA of fetal liver (type A), HepG2 cells (type B), and placenta (type C). Both the cancer and non-cancerous tissues of the resected liver were analyzed. The correlations between the expression of gamma-GTP and the clinicopathological variables and outcomes (recurrence and survival) were studied.
RESULTS: Those with type B gamma-GTP mRNA in cancer had significant higher recurrence rate than those without it (63.6 % vs 14.3 %). Both those with type B in cancer and in non-cancer died significantly more than those without it (45.5 % vs 0 % and 53.6 % vs 0 %, respectively). By multivariate analysis, the significant predictors of recurrence included high serum AFP (P=0.0108), vascular permeation (P=0.0084), and type B gamma-GTP mRNA in non-cancerous liver (P=0.0107). The significant predictors of post-recurrence death included high serum AFP (P=0.0141), vascular permeation (P=0.0130), and daughter nodules (P=0.0053). As to the manifestations (recurrent number >=2, recurrent extent >=2 segments, extra-hepatic metastasis, and death) in recurrent patients, there were no statistical significant differences between those with type B in the primary tumor and those without it. The difference between those with type B in non-cancerous liver and those without it also was not significant.
CONCLUSION: Patients of HCC with type B gamma-GTP mRNA both in cancer and in non-cancerous tissue had a worse outcome, earlier recurrence, and more post-recurrence death.
METHODS: Forty consecutive patients having curative resection for HCC were included in this study. The primers for reverse-transcription polymerase chain reaction (RT-PCR) were corresponding to the 5'-noncoding human gamma-GTP mRNA of fetal liver (type A), HepG2 cells (type B), and placenta (type C). Both the cancer and non-cancerous tissues of the resected liver were analyzed. The correlations between the expression of gamma-GTP and the clinicopathological variables and outcomes (recurrence and survival) were studied.
RESULTS: Those with type B gamma-GTP mRNA in cancer had significant higher recurrence rate than those without it (63.6 % vs 14.3 %). Both those with type B in cancer and in non-cancer died significantly more than those without it (45.5 % vs 0 % and 53.6 % vs 0 %, respectively). By multivariate analysis, the significant predictors of recurrence included high serum AFP (P=0.0108), vascular permeation (P=0.0084), and type B gamma-GTP mRNA in non-cancerous liver (P=0.0107). The significant predictors of post-recurrence death included high serum AFP (P=0.0141), vascular permeation (P=0.0130), and daughter nodules (P=0.0053). As to the manifestations (recurrent number >=2, recurrent extent >=2 segments, extra-hepatic metastasis, and death) in recurrent patients, there were no statistical significant differences between those with type B in the primary tumor and those without it. The difference between those with type B in non-cancerous liver and those without it also was not significant.
CONCLUSION: Patients of HCC with type B gamma-GTP mRNA both in cancer and in non-cancerous tissue had a worse outcome, earlier recurrence, and more post-recurrence death.